Qureator’s pioneering work in advanced 3D disease modeling was recently spotlighted by the Korean Economic Daily in coverage of our collaboration with SillaJen Inc. The article highlighted how Qureator’s organoid and microphysiological system (MPS) technologies are helping SillaJen optimize the recommended phase 2 dose (RP2D) for its novel cancer drug candidate, BAL0891. Our 3D vascularized tumor models demonstrated a 30% increase in efficacy when BAL0891 was combined with immunotherapy in triple-negative breast cancer models. Congratulations to our collaborator SillaJen on this important milestone! We are proud to support their innovative clinical development strategy and look forward to advancing the future of human-relevant preclinical research together.